Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Arthritis, Rheumatoid Clinical Trial

Official title:

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02602704
• Other study ID #: HUHRD-SPE-15-05
• Secondary ID: WI205578
• Status: Completed
• Phase: Phase 4
• Start date: December 29, 2015
• Est. completion date: December 1, 2018

Study information

• Verified date: August 2020
• Source: Hanyang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• The purpose of this study is to study the effectiveness of bazedoxifene in preventing loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.

• This is a randomized, controlled, open-label extension study for 48 or 56 weeks. At study entry, all patients will receive elemental calcium (1200 mg daily) and vitamin D (800 IU daily) and will be randomized by blocks of two to receive either bazedoxifene (20 mg/day) or none.

Description:

• The purpose of this study is to study the effectiveness of bazedoxifene in preventing loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.

• This was a randomized, controlled, open-label study conducted for 56 weeks. Four trial visits occurred over the course of the 56 weeks. At study entry, all patients who took elemental calcium (1200 mg daily) and vitamin D (800 IU daily) were assigned by blocks of two to receive either bazedoxifene (20 mg/day) (bazedoxifene group) or not (control group).

• Randomization was performed by an independent coordinator. Participants were followed-up at 24 weeks and 48 weeks with special attention to RA flares and occurrence of AEs.

• Demographic characteristics such as age, sex, and medications related to RA, as well as laboratory result such as complete blood count (CBC), chemistry, and levels of inflammatory markers were collected at enrollment. BMD and trabecular bone score (TBS) were assessed at 0 and 48 weeks, and levels of bone turnover markers were assessed at 0, 24, and 48 weeks. At 56 weeks, the occurrence of AEs was assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: December 1, 2018
• Est. primary completion date: October 11, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

• Female RA patients = 45 years old with self-reported postmenopausal for =12 months or prior hysterectomy with bilateral oophorectomy. Female patients = 55 years old who had prior hysterectomy without oophorectomy or with unilateral oophorectomy.

• Having been receiving low to moderate dose of glucocorticoids (prednisone =7.5 mg/day or equivalent) for =3 months prior to entry. (When taking glucocorticoids PRN, prednisone =1mg/day in average.)

• Patients expected to be on glucocorticoid treatment for 3 months after entry.

• Patients with an osteopenic mean lumbar spine (LS; L1-L4) or femoral neck bone mineral density (BMD; -1 < T-score < -2.5)

• Patients who provide a written consent of participating in this study.

Exclusion Criteria:

• Patients with condition that may interfere with the evaluation of spinal or hip osteoporosis by DXA such as two or more vertebral (L1-L4) fractures or other vertebral deformity

• Patients with hypercoagulability risk factors or a history of deep vein thrombosis and pulmonary embolism

• History of allergic reactions or intolerance to bazedoxifene or other SERM

• Patients receiving bisphosphonates, parathyroid hormone, SERMs, or anticonvulsants therapies within 6 months prior to entry

• Patients with known bone disorders such as osteomalacia, renal osteodystrophy and hyperparathyroidism

• Patients with undiagnosed uterine bleeding

• Patients with severe renal impairment or creatinine clearance <30ml/min

Related Conditions & MeSH terms

• Arthritis, Rheumatoid

Intervention

Drug:
• Bazedoxifene
Bazedoxifene 20mg/day (Viviant) for 48 weeks
• Calcium/Vit D
Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks

Locations

Country	Name	City	State
Korea, Republic of	Hanyang University	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Hanyang University	Pfizer

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Bone Mineral Density (BMD)	BMD of the L-spine (L1-4) and femur neck was assessed by dual-energy x-ray absorptiometry (DXA) (Hologic®, Discovery W, Hologic APEX software version 2.3.1; Bedford, MA, USA). BMD in the L-spine was estimated as the mean of individual measurements for L1-L4 excluding any fractured or otherwise deformed vertebrae. The technician who was responsible for measuring BMD was blinded to the details of the study.	Baseline and 48 weeks
Secondary	Change of Trabecular Bone Score (TBS)	Lumbar spine TBS is obtained using the spine DXA scan archived from the baseline and 48 weeks tests. It is calculated after reanalysis of the DXA scan of the L-spine using TBS iNsight® software (Version 2.0.0.1, Med-Imaps, Bordeaux, France). Vertebrae excluded in the calculation of BMD are also excluded in the TBS calculation.	Baseline and 48 weeks
Secondary	Development of the thoracic and lumbar vertebrae for deformities by visual inspection	Baseline vertebral fracture is defined as a loss of at least 25% of vertebral height through the thoracic spine X-ray and the lumbar spine X-ray. Incident vertebral fractures at 48 weeks is diagnosed when there were distinct alterations in the morphology of the vertebral bodies that resulted in the loss of at least 25% of vertebral height of previously normal vertebrae.; The location, the date of occurrence and the severity of fracture (mild, moderate, severe, etc.) are described.	Baseline and 48 weeks
Secondary	Development of any fractures including nonvertebral fractures	Measured by the questionnaire for fracture. Check item: the location and the date of occurrence of fracture.	Baseline, 24 weeks and 48 weeks
Secondary	Change in serum C-terminal telopeptide (CTX)	Serum C-telopeptide levels (ng/ml) are assayed by electrochemiluminescence (Roche Diagnostics, GmbH, Mannheim, Germany). Blood samples are collected after at least an 8-hour fast.	Baseline, 24 weeks and 48 weeks
Secondary	Change in urine N-telopeptide (NTX)	Urine N-telopeptide levels (ng/ml) are measured by chemiluminescence (Ortho Clinical Diagnostics, New York, USA) using commercially available kits. Urine samples are collected after at least an 8-hour fast.	Baseline, 24 weeks and 48 weeks
Secondary	Change in serum bone specific alkaline phosphatase	Serum bone-specific alkaline phosphatase (ALP) levels (µg/L) are also determined by electrochemiluminescence using commercial kits (Beckman Coulter Inc., Brea, USA). Blood samples are collected after at least an 8-hour fast.	Baseline, 24 weeks and 48 weeks
Secondary	Change in serum osteocalcin	Serum osteocalcin levels (ng/mL) are also determined by electrochemiluminescence using commercial kits (Beckman Coulter Inc., Brea, USA). Blood samples are collected after at least an 8-hour fast.	Baseline, 24 weeks and 48 weeks